Stokes Family Office LLC Has $1.50 Million Stock Holdings in Inogen, Inc. (NASDAQ:INGN)

Stokes Family Office LLC grew its position in Inogen, Inc. (NASDAQ:INGN) by 29.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 163,500 shares of the medical technology company’s stock after purchasing an additional 36,715 shares during the period. Stokes Family Office LLC owned about 0.69% of Inogen worth $1,499,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. AlphaQuest LLC acquired a new stake in Inogen in the fourth quarter worth $43,000. Quarry LP bought a new position in Inogen in the third quarter valued at $59,000. Intech Investment Management LLC acquired a new stake in Inogen in the fourth quarter valued at $94,000. Ieq Capital LLC acquired a new stake in Inogen in the fourth quarter valued at $94,000. Finally, Verition Fund Management LLC acquired a new stake in Inogen in the third quarter valued at $106,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Inogen Stock Down 2.3 %

Inogen stock opened at $7.33 on Wednesday. The company has a market capitalization of $194.46 million, a PE ratio of -3.26 and a beta of 1.15. The firm’s fifty day moving average is $9.88 and its 200 day moving average is $9.76. Inogen, Inc. has a 12-month low of $6.14 and a 12-month high of $13.33.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research note on Wednesday, February 26th. StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.